Published in Hernia on April 09, 2013
Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene (1999) 2.10
Desmoid tumours in familial adenomatous polyposis. Gut (1994) 2.08
The latent period in carcinogenesis by plastics in rats and its relation to the presarcomatous stage. Cancer (1958) 1.90
Nuclear beta-catenin expression distinguishes deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions. Am J Surg Pathol (2005) 1.88
Current ideas in desmoid tumours. Fam Cancer (2006) 1.82
Beta-catenin immunohistochemistry separates mesenteric fibromatosis from gastrointestinal stromal tumor and sclerosing mesenteritis. Am J Surg Pathol (2002) 1.74
From the archives of the AFIP: musculoskeletal fibromatoses: radiologic-pathologic correlation. Radiographics (2009) 1.67
Desmoid tumour: a pleomorphic lesion. Eur J Surg Oncol (1999) 1.54
Evidence for genetic predisposition to desmoid tumours in familial adenomatous polyposis independent of the germline APC mutation. Gut (2004) 1.42
Evaluation of new prosthetic meshes for ventral hernia repair. Surg Endosc (2006) 1.32
Frequent mutations in the beta-catenin gene in desmoid tumors from patients without familial adenomatous polyposis. Oncol Res (1998) 1.31
Fibromatosis of the breast and mutations involving the APC/beta-catenin pathway. Hum Pathol (2002) 1.12
Tissue ingrowth and bowel adhesion formation in an animal comparative study: polypropylene versus Proceed versus Parietex Composite. Surg Endosc (2007) 1.11
Carcinogenic potential of commonly used hernia repair prostheses in an experimental model. Br J Surg (2004) 0.94
A massive abdominal wall desmoid tumor occurring in a laparotomy scar: a case report. World J Surg Oncol (2011) 0.91
Desmoid tumor arising in a laparoscopic trocar site. Am Surg (1998) 0.84
Soft tissue tumors following traumatic injury: two observations of interest for the medicolegal causality. Am J Forensic Med Pathol (1998) 0.83
Desmoid tumor arising at the colostomy site after abdominoperineal resection for rectal carcinoma: report of a case. Dis Colon Rectum (2006) 0.78
[Desmoid tumor arising in a laparoscopic trocar site after cholectomy]. Rev Esp Enferm Dig (2009) 0.78
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
Laparoscopic versus minilaparotomy cholecystectomy: a randomised trial. Lancet (1994) 3.29
High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A (1992) 3.22
Randomized clinical trial of the effect of postoperative intravenous fluid restriction on recovery after elective colorectal surgery. Br J Surg (2006) 2.66
Surgical site infection after groin hernia repair. Br J Surg (2004) 2.54
Outcome of patients with severe chronic pain following repair of groin hernia. Br J Surg (2002) 2.38
Five-year follow-up of a randomized trial to assess pain and numbness after laparoscopic or open repair of groin hernia. Br J Surg (2004) 2.20
A case of a Spigelian hernia at an unusually high anatomical location. J R Coll Surg Edinb (2000) 2.18
Chronic groin sepsis following tension-free inguinal hernioplasty. Br J Surg (1999) 2.15
Phase I clinical trial design in cancer drug development. J Clin Oncol (2000) 2.14
Effect of a no-conversion policy on patient outcome following laparoscopic cholecystectomy. Br J Surg (1997) 2.13
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer (2011) 1.99
Groin hernia repair in Scotland. Br J Surg (2000) 1.93
Bile duct injury and bile leakage in laparoscopic cholecystectomy. Br J Surg (1995) 1.87
Long-term follow-up of patients with a painless inguinal hernia from a randomized clinical trial. Br J Surg (2010) 1.83
Laparoscopic colonic resection in fast-track patients does not enhance short-term recovery after elective surgery. Colorectal Dis (2007) 1.71
Preventing complications of laparoscopy. Br J Surg (1993) 1.70
Effect of closing dead space on seroma formation after mastectomy--a prospective randomized clinical trial. Eur J Surg Oncol (1993) 1.69
Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol (1995) 1.67
A randomized comparison of driver reaction time after open and endoscopic tension-free inguinal hernia repair. Surg Endosc (1999) 1.60
Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer. J Clin Oncol (2001) 1.50
Plasma gastrin concentrations are normal in patients with colorectal neoplasia and unaltered following tumor resection. Gastroenterology (1994) 1.50
Laparoscopic or minilaparotomy cholecystectomy? BMJ (1992) 1.50
Evaluation of the long term outcome of patients with extremity desmoids. Eur J Surg Oncol (2004) 1.48
Efficacy of tumoricidal agents in vitro and in vivo. Br J Surg (1995) 1.47
Value of biopsy in the assessment of a retroperitoneal mass. Surgeon (2006) 1.47
Randomized trial of different insufflation pressures for laparoscopic cholecystectomy. Br J Surg (1997) 1.47
Symptomatic outcome 1 year after laparoscopic and minilaparotomy cholecystectomy: a randomized trial. Br J Surg (1995) 1.44
Effect of suture material on tumour cell adherence at sites of colonic injury. Br J Surg (1993) 1.43
Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer (2005) 1.42
Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia. Mol Cell Biol (1994) 1.39
Laparoscopic and minilaparotomy cholecystectomy: a randomized trial comparing postoperative pain and pulmonary function. Surgery (1994) 1.38
Randomized clinical trial comparing consultant-led or open access investigation for large bowel symptoms. Br J Surg (2003) 1.38
Impact of video colonoscopy on stage and outcome of patients with symptomatic colorectal cancer. Surg Endosc (2004) 1.38
Hernias are the most common cause of strangulation in patients presenting with small bowel obstruction. Hernia (2006) 1.36
Pain from primary inguinal hernia and the effect of repair on pain. Br J Surg (2002) 1.32
The role of laparoscopic adrenalectomy for adrenal tumours of 6 cm or greater. Surg Endosc (2007) 1.31
Etoposide (VP-16-213). Current status of an active anticancer drug. N Engl J Med (1985) 1.23
Early outcome after open versus extraperitoneal endoscopic tension-free hernioplasty: a randomized clinical trial. Surgery (1996) 1.21
The learning curve for laparoscopic hernia repair. Semin Laparosc Surg (1998) 1.18
The measurement of chronic pain and health-related quality of life following inguinal hernia repair: a review of the literature. Hernia (2008) 1.16
Diagnosis of a femoral hernia in the elective setting. J R Coll Surg Edinb (2001) 1.13
What effect does the duration of an inguinal hernia have on patient symptoms? J Am Coll Surg (2001) 1.12
Effects of urotensin II in human arteries and veins of varying caliber. Circulation (2001) 1.12
C-reactive protein as a predictor of postoperative infective complications following elective colorectal resection. Colorectal Dis (2011) 1.12
Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res (1993) 1.11
Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res (1995) 1.11
Prospective study on the role of C-reactive protein (CRP) in patients with an acute abdomen. Ann R Coll Surg Engl (2007) 1.10
Prospective study on the management of patients with complicated diverticular disease. Colorectal Dis (2006) 1.08
Early discharge following liver resection for colorectal metastases. Scott Med J (2008) 1.05
Effect of surgeon specialty interest on patient outcome after potentially curative colorectal cancer surgery. Dis Colon Rectum (2000) 1.04
Clinical studies of reversal of drug resistance based on glutathione. Chem Biol Interact (1998) 1.03
Phase I/pharmacokinetic trial of the novel thioxanthone SR233377 (WIN33377) on a 5-day schedule. Cancer Chemother Pharmacol (1999) 1.02
Effect of time interval between surgery and preoperative chemoradiotherapy with 5-fluorouracil or 5-fluorouracil and oxaliplatin on outcomes in rectal cancer. J Surg Oncol (2007) 1.02
Apoptosis in human adenocarcinoma HT29 cells induced by exposure to hypoxia. J Natl Cancer Inst (1995) 1.02
Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res (1994) 1.01
Axillary dissection in primary breast cancer. BMJ (1991) 1.01
Antisense therapeutics: lessons from early clinical trials. Curr Opin Oncol (2001) 0.99
Ventral hernia repair: a study of current practice. Hernia (2003) 0.99
Surgeon perspectives on options for ventral abdominal wall hernia repair: results of a postal questionnaire. Hernia (2005) 0.98
Glutathione and drug resistance. Cancer Invest (1996) 0.95
Prospective study on the role of the CT scan in patients with an acute abdomen. Colorectal Dis (2005) 0.95
Effect of the surgeon's specialty interest on the type of resection performed for colorectal cancer. Dis Colon Rectum (1994) 0.95
Carcinogenic potential of commonly used hernia repair prostheses in an experimental model. Br J Surg (2004) 0.94
Involvement of NF-kappa B in the induction of NAD(P)H:quinone oxidoreductase (DT-diaphorase) by hypoxia, oltipraz and mitomycin C. Biochem Pharmacol (1995) 0.94
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. Br J Cancer (2005) 0.94
Intraoperative probe-directed immunodetection using a monoclonal antibody. Arch Surg (1986) 0.94
Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J Clin Oncol (1999) 0.93
MAX2--a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials. Eur J Cancer (2004) 0.93
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Ann Oncol (2007) 0.93
In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo. Br J Cancer (2005) 0.93
A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol (1985) 0.92
Changes in the concentrations of plasma selenium and selenoproteins after minor elective surgery: further evidence for a negative acute phase response? Clin Chem (1998) 0.90
Clinicopathological study of perineal Paget's disease. Br J Surg (1997) 0.90
Gene expression profiling of human ovarian tumours. Br J Cancer (2006) 0.90
Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review. Cancer Res (1988) 0.89
Ventilatory and blood gas changes during laparoscopic and open cholecystectomy. Br J Surg (1993) 0.88
Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas. Invest New Drugs (1996) 0.87
Sensitivity of double contrast barium enema and colonoscopy for the detection of colorectal neoplasms. Surg Endosc (2001) 0.87
A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma. Ann Oncol (2013) 0.87
Safety and efficacy of percutaneous vertebroplasty in malignancy: a systematic review. Clin Radiol (2010) 0.87
Prospective study on the presentation and outcome of patients with an acute hernia. Hernia (2005) 0.86
A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia. J Clin Oncol (1991) 0.86
Effects of geldanamycin on signaling through activator-protein 1 in hypoxic HT29 human colon adenocarcinoma cells. Cancer Res (1999) 0.86
Role of thymidine in biochemical modulation: a review. Cancer Res (1987) 0.86
Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment. Cancer Res (1993) 0.85
Pharmakokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer. J Pharmacol Exp Ther (1994) 0.85
Effects of laparoscopy on intraperitoneal tumor growth and distant metastases in an animal model. Surgery (1999) 0.85
Acivicin: a new glutamine antagonist in clinical trials. J Clin Oncol (1984) 0.84
Effect of extraperitoneal carbon dioxide insufflation on intraoperative blood gas and hemodynamic changes. Surg Endosc (1995) 0.84
Radioimmunoguided surgery using the monoclonal antibody B72.3 in colorectal tumors. Dis Colon Rectum (1987) 0.84
Alternative splicing and differential expression of DT-diaphorase transcripts in human colon tumors and in peripheral mononuclear cells in response to mitomycin C treatment. Cancer Res (1996) 0.84
Acquired abnormalities of the biliary tract from chronic gallstone disease. J Am Coll Surg (1999) 0.84
Recruitment to multicentre trials: the impact of external influences. Health Bull (Edinb) (2000) 0.84
Frequency of early colorectal cancer in patients undergoing colonoscopy. Br J Surg (1999) 0.83
Flavone acetic acid (LM 975, NSC 347512). A novel antitumor agent. Cancer Chemother Pharmacol (1987) 0.83
Comparison of metabolic responses to laparoscopic and minilaparotomy cholecystectomy. Br J Surg (1993) 0.83